The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
The COVID-19 pandemic and the use of MS disease-modifying therapies
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
First case of 2019 novel coronavirus in the United States
Holshue, M. L., DeBolt, C., Lindquist, S., Lofy, K. H., Wiesman, J., Bruce, H., Spitters, C., Ericson, K., Wilkerson, S., Tural, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001191 · Cited by 6,030
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
Hauser, S. L., Bar-Or, A., Comi, G., Giovannoni, G., Hartung, H.-P., Hemmer, B., Lublin, F., Montalban, X., Rammohan, K. W., Selmaj, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1601277 · Cited by 2,021
Self-citationOcrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., de Seze, J., Giovannoni, G., Hartung, H.-P., Hemmer, B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606468 · Cited by 1,905 · cited 1×
“In the phase 3 relapsing-remitting and primary progressive trials, infections were slightly more frequent on ocrelizumab compared to comparator arms (interferon-beta-1a or placebo) Montalban et al., 2017) .”
BackgroundSelf-citationLuna, G., Alping, P., Burman, J., Fink, K., Fogdell-Hahn, A., Gunnarsson, M., Hillert, J., Langer-Gould, A., Lycke, J., Nilsson, P., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2019.3365 · Cited by 521 · cited 1×
“Overall infectious complications are relatively low on S1P modulators, with opportunistic infections emerging over time (Epstein et al., 2018; Luna et al., 2019).”
Background
Cited by
Louapre, C., Collongues, N., Stankoff, B., Giannesini, C., Papeix, C., Bensa, C., Deschamps, R., Créange, A., Wahab, A., Pelletier, J., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.2581 · Cited by 455
The Role of Lipid Metabolism in COVID-19 Virus Infection and as a Drug Target
Abu-Farha, M., Thanaraj, T. A., Qaddoumi, M. G., Hashem, A., Abubaker, J., & Al-Mulla, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103544 · Cited by 300
COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases
Baker, D., Roberts, C. A. K., Pryce, G., Kang, A. S., Marta, M., Reyes, S., Schmierer, K., Giovannoni, G., & Amor, S. (2020) · Clinical and Experimental Immunology · doi:10.1111/cei.13495 · Cited by 192
Self-citationMontero-Escribano, P., Matías-Guiu, J., Gómez-Iglesias, P., Porta-Etessam, J., Pytel, V., & Matias-Guiu, J. A. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.102185 · Cited by 128
“Besides, Prof. Giovannoni's editorial reviews the evidence supporting the hypothesis that immunosuppression of patients with MS on certain disease-modifying therapies may protect of severe COVID-19 infection (Giovannoni, 2020).”
Basu, S., Chakraborty, S., Hassan, A., Siddique, S., & Anand, A. (2020) · Proceedings of the First Workshop on Scholarly Document Processing · doi:10.18653/v1/2020.sdp-1.15 · Cited by 8
Metadata
- Authors
- Giovannoni, G., Hawkes, C., Lechner-Scott, J., Levy, M., Waubant, E., & Gold, J.
- Venue
- Multiple Sclerosis and Related Disorders
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 39
- Pages
- 102073
- ISSN
- 2211-0348 (ISSN-L)
- OpenAlex
- W3013987649
- Cited by
- 191
- References
- 4
- FWCI
- 25.33
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The COVID-19 pandemic and the use of MS disease-modifying therapies. https://app.cochat.ai/papers/10.1016/j.msard.2020.102073
- The paper
- Giovannoni, G., Hawkes, C., Lechner-Scott, J., Levy, M., Waubant, E., & Gold, J. (2020). The COVID-19 pandemic and the use of MS disease-modifying therapies. Multiple Sclerosis and Related Disorders. https://doi.org/10.1016/j.msard.2020.102073
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.